A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure

International Journal of Clinical Practice

Volumn 59, Issue 5, 2005, Pages 571-578

  Erhardt, Leif R ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Chronic heart failure; Clinical outcomes; Pharmacology; Treatment

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRADYKININ; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; LOSARTAN; METOPROLOL; PLACEBO; SPIRONOLACTONE; VALSARTAN; BENZIMIDAZOLE DERIVATIVE; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ACUTE HEART INFARCTION; ANGIONEUROTIC EDEMA; CLINICAL TRIAL; COUGHING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; META ANALYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW; TASTE DISORDER; CONGESTIVE HEART FAILURE; DRUG COMBINATION; DRUG TOLERANCE; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; CAPTOPRIL; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HEART FAILURE, CONGESTIVE; HUMANS; LOSARTAN; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 26944447789     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00513.x     Document Type: Review

References (49)

1. Bayliss J, Norell M, Canepa-Anson R et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987; 57: 17-22.
2. Levy D, Kenchaiah S, Larson MG et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-402.
3. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-35.
4. The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl Med 1991; 325: 293-302.
5. Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355: 1575-81.
6. Cibis-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
7. Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
8. Packer M, Coats AJS, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl Med 2001 ; 344: 1651-8.
9. Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001; 104: 2996-3007.
10. Task Force of the Working Group on heart failure for the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997; 18: 736-53.
11. Guideline Committee members of the Heart Failure Society of America. HFSA guidelines for management of patients with heart failure caused by left ventricular dysfunction: pharmacological approaches. J Cardiac Failure 1999; 5: 357-82.
12. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17.
13. Pitt B, Remme WJ, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
14. Urata H, Healy B, Stewart RW et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-90.
15. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Pressure 2003; 12: 70-88.
16. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95: 1115-8.
17. Struthers A. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996; 2: 47-54.
18. Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004; 6: 539-45.
19. Unger T. The pharmacology of ATI-receptor blockers. Blood Pressure 2001; 10 (Suppl. 3): 5-10.
20. Hubner R, Hogemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997; 11 (Suppl. 2): S19-25.
21. Timmermans PB. Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol 1999; 15 (Suppl. F): 26F-28F.
22. Verheijen I, Fierens FL, Debacker JP et al. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors. Fundam Clin Pharmacol 2000; 14: 577-85.
23. Mcinnes GT. Angiotensin II antagonism in clinical practice: experience with valsartan. J Cardiovasc Pharmacol 1999; 33 (Suppl. 1): S29-32.
24. Morsing P, Vauquelin G. How can the differences among AT1-receptor antagonists be explained? Cell Biochem Biophys 2001; 35: 89-102.
25. Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients. Am J Hypertens 1999; 12: 1181-7.
26. Riegger GAJ, Bouzo H, Petr P et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation 1999; 100: 2224-30.
27. Havranek EP, Thomas I, Smith WB et al. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol 1999; 33: 1174-81.
28. Crozier I, Ikram H, Awan N et al. Losartan in heart failure. Hemodynamic effects and tolerability. Circulation 1995; 91: 691-7.
29. Mitrovic V, Willenbrock R, Miric M et al. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. Am Heart J 2003; 145: E14.
30. Lang RM, Elkayam U, Yellen LG et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J Am Coll Cardiol 1997; 30: 983-91.
31. Dickstein K, Chang P, Willenheimer R et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995; 26: 438-45.
32. Mckelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomised evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999; 100: 1056-64.
33. Baruch L, Anand I, Cohen IS et al. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999; 99: 2658-64.
34. Latini R, Masson S, Anand I et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106: 2454-8.
35. Wong M, Staszewsky L, Latini R et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002; 40: 970-5vi.
36. Hamroff G, Katz SD, Mancini D et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999; 99: 990-2.
37. Mckelvie RS, Rouleau JL, White M et al. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J 2003; 24: 1727-34.
38. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 752-60.
39. Pfeffer MA, Mcmurray JJV, Velasquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-906.
40. Matsumori A. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 2003; 5: 669-77.
41. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure; randomised trial -the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.
42. Pitt B, Segal R, Martinez FA. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997; 349: 747-52.
43. Cohn JN, Tognoni G. A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
44. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.
45. Mcmurray JJV, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71.
46. Granger CB, Mcmurray JJV, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-6.
47. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003; 362: 777-81.
48. Young JB, Dunlap ME, Pfeffer MA et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction. Results of the CHARM Low-Left Ventricular Ejection Fraction trials. Circulation 2004; 110: 2618-26.
49. Ostergren J, Mcmurray JJV. Angiotensin receptor blockers in heart failure. J Renin Angiotensin Aldosterone Syst 2003; 4: 171-5.